Published • loading... • Updated
Novo Nordisk Stock: The First Fruits Of Labor (NYSE:NVO)
Novo Nordisk’s weight-loss and diabetes drugs made up more than three-quarters of first-quarter sales as competition pressures Ozempic and Wegovy.
Summary by Seeking Alpha
2 Articles
2 Articles
Buy, Sell, or Hold Novo Nordisk at $46?
Key PointsThe bulk of Novo Nordisk's sales come from weight-loss and diabetes treatments.The biotech faces competition from companies like Eli Lilly and Pfizer, among others.10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) shares have continued their underperformance -- losing 7.5% so far this year compared to the S&P 500 index's 8% gain. Of course, that's in the past. Current and potential Novo Nordisk shareholders want to …
·Alexandria, United States
Read Full Article
Coverage Details
Total News Sources2
Leaning Left1Leaning Right1Center0Last UpdatedBias Distribution50% Left, 50% Right
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
50% Right
L 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
